Tumor molecular profiling has revealed certain indicators of higher rates of pCR, such as lower estrogen receptor expression, elevated levels of HER2 amplification, and the HER2-enriched PAM50 molecular subtype [17,18,19]. This evidence concerns the gene ERBB2 and neoplasm.